These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 15125963

  • 21. Sulfonamidolactam inhibitors of coagulation factor Xa.
    Smallheer JM, Wang S, Laws ML, Nakajima S, Hu Z, Han W, Jacobson I, Luettgen JM, Rossi KA, Rendina AR, Knabb RM, Wexler RR, Lam PY, Quan ML.
    Bioorg Med Chem Lett; 2008 Apr 01; 18(7):2428-33. PubMed ID: 18329876
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
    Koshio H, Hirayama F, Ishihara T, Kaizawa H, Shigenaga T, Taniuchi Y, Sato K, Moritani Y, Iwatsuki Y, Uemura T, Kaku S, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S.
    Bioorg Med Chem; 2004 Oct 15; 12(20):5415-26. PubMed ID: 15388168
    [Abstract] [Full Text] [Related]

  • 24. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.
    Hirayama F, Koshio H, Ishihara T, Hachiya S, Sugasawa K, Koga Y, Seki N, Shiraki R, Shigenaga T, Iwatsuki Y, Moritani Y, Mori K, Kadokura T, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S.
    J Med Chem; 2011 Dec 08; 54(23):8051-65. PubMed ID: 21995444
    [Abstract] [Full Text] [Related]

  • 25. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
    Phillips G, Davey DD, Eagen KA, Koovakkat SK, Liang A, Ng HP, Pinkerton M, Trinh L, Whitlow M, Beatty AM, Morrissey MM.
    J Med Chem; 1999 May 20; 42(10):1749-56. PubMed ID: 10346927
    [Abstract] [Full Text] [Related]

  • 26. Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation.
    Young WB, Sprengeler P, Shrader WD, Li Y, Rai R, Verner E, Jenkins T, Fatheree P, Kolesnikov A, Janc JW, Cregar L, Elrod K, Katz B.
    Bioorg Med Chem Lett; 2006 Feb 20; 16(3):710-3. PubMed ID: 16257204
    [Abstract] [Full Text] [Related]

  • 27. Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors.
    Franciskovich JB, Masters JJ, Weber WW, Klimkowski VJ, Chouinard M, Sipes PR, Johnson LM, Snyder DW, Chastain MK, Craft TJ, Towner RD, Gifford-Moore DS, Froelich LL, Smallwood JK, Foster RS, Smith GF, Liebeschuetz JW, Murray CW, Young SC.
    Bioorg Med Chem Lett; 2007 Dec 15; 17(24):6910-3. PubMed ID: 17976987
    [Abstract] [Full Text] [Related]

  • 28. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
    Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, Wong PW, Edwards ST, Arfsten AE, Clizbe LA, Kanter J, Pandey A, Park G, Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu BY.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2179-85. PubMed ID: 19297154
    [Abstract] [Full Text] [Related]

  • 29. Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.
    Ueno H, Yokota K, Hoshi J, Yasue K, Hayashi M, Hase Y, Uchida I, Aisaka K, Katoh S, Cho H.
    J Med Chem; 2005 May 19; 48(10):3586-604. PubMed ID: 15887966
    [Abstract] [Full Text] [Related]

  • 30. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
    Lam PY, Clark CG, Li R, Pinto DJ, Orwat MJ, Galemmo RA, Fevig JM, Teleha CA, Alexander RS, Smallwood AM, Rossi KA, Wright MR, Bai SA, He K, Luettgen JM, Wong PC, Knabb RM, Wexler RR.
    J Med Chem; 2003 Oct 09; 46(21):4405-18. PubMed ID: 14521405
    [Abstract] [Full Text] [Related]

  • 31. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
    Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, Reinemer P, Perzborn E.
    J Med Chem; 2005 Sep 22; 48(19):5900-8. PubMed ID: 16161994
    [Abstract] [Full Text] [Related]

  • 32. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J, Deng H, Jin L, Pandey P, Quinn J, Cantin S, Rynkiewicz MJ, Gorga JC, Bibbins F, Celatka CA, Nagafuji P, Bannister TD, Meyers HV, Babine RE, Hayward NJ, Weaver D, Benjamin H, Stassen F, Abdel-Meguid SS, Strickler JE.
    J Med Chem; 2006 Dec 28; 49(26):7781-91. PubMed ID: 17181160
    [Abstract] [Full Text] [Related]

  • 33. Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element.
    Pandya V, Jain M, Chakrabarti G, Soni H, Parmar B, Chaugule B, Patel J, Jarag T, Joshi J, Joshi N, Rath A, Unadkat V, Sharma B, Ajani H, Kumar J, Sairam KV, Patel H, Patel P.
    Eur J Med Chem; 2012 Dec 28; 58():136-52. PubMed ID: 23124211
    [Abstract] [Full Text] [Related]

  • 34. Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.
    Chan C, Borthwick AD, Brown D, Burns-Kurtis CL, Campbell M, Chaudry L, Chung CW, Convery MA, Hamblin JN, Johnstone L, Kelly HA, Kleanthous S, Patikis A, Patel C, Pateman AJ, Senger S, Shah GP, Toomey JR, Watson NS, Weston HE, Whitworth C, Young RJ, Zhou P.
    J Med Chem; 2007 Apr 05; 50(7):1546-57. PubMed ID: 17338508
    [Abstract] [Full Text] [Related]

  • 35. Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa.
    Ueno H, Katoh S, Yokota K, Hoshi J, Hayashi M, Uchida I, Aisaka K, Hase Y, Cho H.
    Bioorg Med Chem Lett; 2004 Aug 16; 14(16):4281-6. PubMed ID: 15261287
    [Abstract] [Full Text] [Related]

  • 36. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW, Dorsch D, Anzali S, Gleitz J, Cezanne B, Tsaklakidis C.
    Bioorg Med Chem Lett; 2004 Jul 16; 14(14):3763-9. PubMed ID: 15203158
    [Abstract] [Full Text] [Related]

  • 37. Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165.
    Hosaka Y, Matsumoto M, Shinozaki M, Ohno T, Yatagai Y, Kamiya M, Kurokawa M, Nishida H, Matsusue T, Mizuguchi K, Ishii H.
    Eur J Pharmacol; 2006 Jan 04; 529(1-3):164-71. PubMed ID: 16316651
    [Abstract] [Full Text] [Related]

  • 38. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
    Quan ML, Han Q, Fevig JM, Lam PY, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR.
    Bioorg Med Chem Lett; 2006 Apr 01; 16(7):1795-8. PubMed ID: 16434195
    [Abstract] [Full Text] [Related]

  • 39. Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW, Cezanne B, van Amsterdam C, Bühring KU, Dorsch D, Gleitz J, März J, Tsaklakidis C.
    Bioorg Med Chem Lett; 2004 Dec 06; 14(23):5817-22. PubMed ID: 15501047
    [Abstract] [Full Text] [Related]

  • 40. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
    Lee K, Park CW, Jung WH, Park HD, Lee SH, Chung KH, Park SK, Kwon OH, Kang M, Park DH, Lee SK, Kim EE, Yoon SK, Kim A.
    J Med Chem; 2003 Aug 14; 46(17):3612-22. PubMed ID: 12904065
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.